Cargando…

A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR

BACKGROUND: Prostate cancer (CaP) is one of the most relevant causes of cancer death in Western Countries. Although detection of CaP at early curable stage is highly desirable, actual screening methods present limitations and new molecular approaches are needed. Gene expression analysis increases ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzi, Federica, Belloni, Lucia, Crafa, Pellegrino, Lazzaretti, Mirca, Remondini, Daniel, Ferretti, Stefania, Cortellini, Piero, Corti, Arnaldo, Bettuzzi, Saverio
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570792/
https://www.ncbi.nlm.nih.gov/pubmed/18974881
http://dx.doi.org/10.1371/journal.pone.0003617
_version_ 1782160172439830528
author Rizzi, Federica
Belloni, Lucia
Crafa, Pellegrino
Lazzaretti, Mirca
Remondini, Daniel
Ferretti, Stefania
Cortellini, Piero
Corti, Arnaldo
Bettuzzi, Saverio
author_facet Rizzi, Federica
Belloni, Lucia
Crafa, Pellegrino
Lazzaretti, Mirca
Remondini, Daniel
Ferretti, Stefania
Cortellini, Piero
Corti, Arnaldo
Bettuzzi, Saverio
author_sort Rizzi, Federica
collection PubMed
description BACKGROUND: Prostate cancer (CaP) is one of the most relevant causes of cancer death in Western Countries. Although detection of CaP at early curable stage is highly desirable, actual screening methods present limitations and new molecular approaches are needed. Gene expression analysis increases our knowledge about the biology of CaP and may render novel molecular tools, but the identification of accurate biomarkers for reliable molecular diagnosis is a real challenge. We describe here the diagnostic power of a novel 8-genes signature: ornithine decarboxylase (ODC), ornithine decarboxylase antizyme (OAZ), adenosylmethionine decarboxylase (AdoMetDC), spermidine/spermine N(1)-acetyltransferase (SSAT), histone H3 (H3), growth arrest specific gene (GAS1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Clusterin (CLU) in tumour detection/classification of human CaP. METHODOLOGY/PRINCIPAL FINDINGS: The 8-gene signature was detected by retrotranscription real-time quantitative PCR (RT-qPCR) in frozen prostate surgical specimens obtained from 41 patients diagnosed with CaP and recommended to undergo radical prostatectomy (RP). No therapy was given to patients at any time before RP. The bio-bank used for the study consisted of 66 specimens: 44 were benign-CaP paired from the same patient. Thirty-five were classified as benign and 31 as CaP after final pathological examination. Only molecular data were used for classification of specimens. The Nearest Neighbour (NN) classifier was used in order to discriminate CaP from benign tissue. Validation of final results was obtained with 10-fold crossvalidation procedure. CaP versus benign specimens were discriminated with (80±5)% accuracy, (81±6)% sensitivity and (78±7)% specificity. The method also correctly classified 71% of patients with Gleason score<7 versus ≥7, an important predictor of final outcome. CONCLUSIONS/SIGNIFICANCE: The method showed high sensitivity in a collection of specimens in which a significant portion of the total (13/31, equal to 42%) was considered CaP on the basis of having less than 15% of cancer cells. This result supports the notion of the “cancer field effect”, in which transformed cells extend beyond morphologically evident tumour. The molecular diagnosis method here described is objective and less subjected to human error. Although further confirmations are needed, this method posses the potential to enhance conventional diagnosis.
format Text
id pubmed-2570792
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-25707922008-10-31 A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR Rizzi, Federica Belloni, Lucia Crafa, Pellegrino Lazzaretti, Mirca Remondini, Daniel Ferretti, Stefania Cortellini, Piero Corti, Arnaldo Bettuzzi, Saverio PLoS One Research Article BACKGROUND: Prostate cancer (CaP) is one of the most relevant causes of cancer death in Western Countries. Although detection of CaP at early curable stage is highly desirable, actual screening methods present limitations and new molecular approaches are needed. Gene expression analysis increases our knowledge about the biology of CaP and may render novel molecular tools, but the identification of accurate biomarkers for reliable molecular diagnosis is a real challenge. We describe here the diagnostic power of a novel 8-genes signature: ornithine decarboxylase (ODC), ornithine decarboxylase antizyme (OAZ), adenosylmethionine decarboxylase (AdoMetDC), spermidine/spermine N(1)-acetyltransferase (SSAT), histone H3 (H3), growth arrest specific gene (GAS1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Clusterin (CLU) in tumour detection/classification of human CaP. METHODOLOGY/PRINCIPAL FINDINGS: The 8-gene signature was detected by retrotranscription real-time quantitative PCR (RT-qPCR) in frozen prostate surgical specimens obtained from 41 patients diagnosed with CaP and recommended to undergo radical prostatectomy (RP). No therapy was given to patients at any time before RP. The bio-bank used for the study consisted of 66 specimens: 44 were benign-CaP paired from the same patient. Thirty-five were classified as benign and 31 as CaP after final pathological examination. Only molecular data were used for classification of specimens. The Nearest Neighbour (NN) classifier was used in order to discriminate CaP from benign tissue. Validation of final results was obtained with 10-fold crossvalidation procedure. CaP versus benign specimens were discriminated with (80±5)% accuracy, (81±6)% sensitivity and (78±7)% specificity. The method also correctly classified 71% of patients with Gleason score<7 versus ≥7, an important predictor of final outcome. CONCLUSIONS/SIGNIFICANCE: The method showed high sensitivity in a collection of specimens in which a significant portion of the total (13/31, equal to 42%) was considered CaP on the basis of having less than 15% of cancer cells. This result supports the notion of the “cancer field effect”, in which transformed cells extend beyond morphologically evident tumour. The molecular diagnosis method here described is objective and less subjected to human error. Although further confirmations are needed, this method posses the potential to enhance conventional diagnosis. Public Library of Science 2008-10-31 /pmc/articles/PMC2570792/ /pubmed/18974881 http://dx.doi.org/10.1371/journal.pone.0003617 Text en Rizzi et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Rizzi, Federica
Belloni, Lucia
Crafa, Pellegrino
Lazzaretti, Mirca
Remondini, Daniel
Ferretti, Stefania
Cortellini, Piero
Corti, Arnaldo
Bettuzzi, Saverio
A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR
title A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR
title_full A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR
title_fullStr A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR
title_full_unstemmed A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR
title_short A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR
title_sort novel gene signature for molecular diagnosis of human prostate cancer by rt-qpcr
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570792/
https://www.ncbi.nlm.nih.gov/pubmed/18974881
http://dx.doi.org/10.1371/journal.pone.0003617
work_keys_str_mv AT rizzifederica anovelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT bellonilucia anovelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT crafapellegrino anovelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT lazzarettimirca anovelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT remondinidaniel anovelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT ferrettistefania anovelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT cortellinipiero anovelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT cortiarnaldo anovelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT bettuzzisaverio anovelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT rizzifederica novelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT bellonilucia novelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT crafapellegrino novelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT lazzarettimirca novelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT remondinidaniel novelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT ferrettistefania novelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT cortellinipiero novelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT cortiarnaldo novelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr
AT bettuzzisaverio novelgenesignatureformoleculardiagnosisofhumanprostatecancerbyrtqpcr